Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07288333
PHASE2

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

Sponsor: Neurocrine Biosciences

View on ClinicalTrials.gov

Summary

The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.

Official title: A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2026-02-16

Completion Date

2027-08

Last Updated

2026-05-26

Healthy Volunteers

No

Conditions

Interventions

DRUG

NBI-1117570

Oral administration

DRUG

Placebo

Oral administration

Locations (5)

Neurocrine Clinical Site

Kazanlak, Bulgaria

Neurocrine Clinical Site

Pazardzhik, Bulgaria

Neurocrine Clinical Site

Targovishte, Bulgaria

Neurocrine Clinical Site

London, United Kingdom

Neurocrine Clinical Site

Oxford, United Kingdom